Kuala Lumpur police chief Commissioner Datuk Saiful Azly Kamaruddin today said soon after the victim received an injection from the beautician, she suffered breathlessness and turned pale.

He said the beautician called for an ambulance and the victim was rushed to a hospital but was pronounced dead by doctors.

Saiful said the 49-year-old beautician and her 23-year-old daughter were arrested following the incident and are being held under a remand order.

He said initial investigations revealed that although the beauty centre was a legally registered business, it was not endorsed by the relevant authorities to perform liposuction procedures.

Saiful said the staff purportedly went ahead with the treatment after being persuaded by the victim.

He said the case in being investigated for causing death by negligence under Section 304 (a) of the Penal Code.

Investigators are waiting for a post-mortem and toxicology report to ascertain what had caused the woman’s death.

The post Woman dies in botched liposuction procedure appeared first on MyMedicPlus.

The European Medicines Agency has approved an injection of AIDS treatment, which sets a precedent for changing the lives of millions of people with HIV, or those known as “seropositive”.The treatment mixes two antiretrovirals, and it can be given to the patient once every month or two, instead of taking daily pills to contain the disease, the agency said in a statement.

The Foundation indicated that these two antagonists are the “first” that are found to have a “long-term” effect through injection.She stated that “patients will receive intramuscular injections once every month or two instead of daily medication pills,” according to “France Press”.

The agency’s recommendation to allow this treatment to be marketed must obtain approval from the European Commission, in order for it to be put on the market in the EU’s 27 countries.

The agency indicated that the combination of the two anti-retroviral drugs “Rilpivirin” and “Capotegravir”, which will be sold under the names of “Recampase” and “Vocabria”, helps in “preventing the ability of the virus to reproduce.”

The number of people living with AIDS in the world reached 38 million in 2019, including 2.3 million in Europe, according to the World Health Organization.This disease has no cure yet, but antiretrovirals can control virus progression and contribute to avoiding transmission.

These were the details of the news A new treatment for AIDS by injection for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

The post A new treatment for AIDS by injection appeared first on MyMedicPlus.

Last week, the FDA denied the approval of Cabenuva, the first of its kind monthly HIV injection treatment. Developers hoped that the monthly injection would replace daily pills, thus making life easier for HIV patients and also possibly removing some of the stigma associated with the disease. 

According to ABC News, the FDA had no concerns with the drug’s efficacy or safety. Rather the application’s denial was due to concerns regarding the drug’s manufacturing process. In their Complete Response Letter (CRL) regarding the New Drug Application, the FDA stated their rejection was related to “Chemistry, Manufacturing, and Controls (CMC),” EMPR reported.

Cabenuva passed trials and proved to be effective at repressing virus levels in HIV-positive patients. New trials will not be required as the FDA denial was not related to concerns with drug safety. Instead, the manufacturers plan to “work closely and with urgency with the FDA to determine the appropriate next steps for this new drug application,” a drug spokesperson told ABC News. 

“Clearly this is disappointing and not the news we hoped for,” said a spokesperson.

HIV is a virus that weakens a person’s immune system by interfering with their ability to fight off infection. Although there is no cure, there are certain medications that can help control the disease by slowing the virus’ progression in the body. These drugs may also aid in lowering an individual’s risk of spreading HIV to others by reducing the amount of the virus in your body, the Center for Disease Control and Prevention report. 

The Cabenuva injection contains two active ingredients (cabotegravir and Janssen’s rilpivirine). The long-lasting drug is administered every four weeks. For some HIV patients there is a fear of stigma associated with their health status. Release from the dependence of daily pills may save some from this stigma. 

In addition to HIV treatment, there are also medications used called PrEP (Pre-Exposure Prophylaxis), which help prevent HIV negative individuals from contracting the virus. The combination of these HIV prevention and treatment medications have helped to slow the rate of HIV transmission in the U.S. and improve the lives of those living with the virus.

Although the FDA cited that there were no concerns with the safety of Cabenuva, doctors express concerns of may come along with a monthly injection versus a daily pill. For example, patients who miss an injection may be at greater risk for the virus to grow in numbers and strength, ABC News reported. 

The drug application was filed by ViiC Healthcare, which is majority-owned by GlaxoSmithKine. Pfizer and Shionogi also have small stakes.

The post Why Did The FDA Deny Approval For A Monthly HIV Injection Treatment? appeared first on MyMedicPlus.

An injection has helped reduce body weight and glucose levels in patients with diabetes and obesity in four weeks.

The findings came from a small study in which patients lost on average 4.4kg and the treatment led to substantial improvements to their blood glucose, with some patients’ reducing to near-normal levels.

Obesity is a common problem in the UK and it is estimated that one in four adults are obese.

One of the most common types of weight loss surgery is a procedure known as gastric bypass surgery, which can be very effective in keeping excess weight off and improving blood sugar levels in diabetics. However, some patients decide against surgery and the procedure can cause complications such as abdominal pain, chronic nausea, vomiting and debilitating low blood sugar levels.

Previous research by Imperial College London suggested that one of the reasons why gastric bypass surgery works so well is because three specific hormones originating from the bowels are released in higher levels. This hormone combination, called “GOP’ for short, reduces appetite, causes weight loss and improves the body’s ability to use the sugar absorbed from eating.

Researchers wanted to see if infusing patients with the GOP hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin and peptide, to mimic the high levels seen after surgery, could aid weight loss and reduce high glucose levels.

Fifteen patients were given the GOP treatment for four weeks using a pump that slowly injects the GOP mixture under the skin for 12 hours a day, beginning one hour before breakfast and disconnecting after their last meal of the day. Patients also received dietetic advice on healthy eating and weight loss from a dietician.

Professor Tricia Tan, Professor of Practice (Metabolic Medicine & Endocrinology) at Imperial College London and lead author of the study, said:

“Obesity and type 2 diabetes can lead to very serious and potentially life-threatening conditions such as cancer, stroke and heart disease. There is a real need to find new medicines so we can improve and save the lives of many patients. Although this is a small study our new combination hormone treatment is promising and has shown significant improvements in patients’ health in only four weeks. Compared to other methods the treatment is non-invasive and reduced glucose levels to near-normal levels in our patients.”

The work, published in Diabetes Care and presented at the American Diabetes Association 79th Scientific Sessions meeting at San Francisco, took place at Imperial College London in collaboration with University of Copenhagen and University College Dublin. The treatment was trialled on patients at the National Institute for Health Research Imperial Clinical Research Facility at Hammersmith Hospital, part of Imperial College Healthcare NHS Trust.

Twenty-six obese patients with prediabetes (when blood glucose is too high but not high enough to be classified as diabetes) and those with diabetes were recruited to the study at Hammersmith Hospital from July 2016 to October 2018. Fifteen patients were randomly selected to receive the hormone treatment and 11 patients were given a saline (salt water) infusion as a placebo over a four-week period. The team also recruited 21 patients who had undergone bariatric surgery and 22 patients who followed a very low-calorie diet to compare the results of GOP. All patients were given a glucose monitoring device to track their glucose levels following treatment.

In the trial, patients on the GOP treatment lost an average of 4.4kg, compared with 2.5kg for participants receiving a saline placebo. The treatment also had no side effects.

However, patients who received bariatric surgery or who followed a very low calorie diet lost significantly more weight than GOP patients. The changes in weight were 10.3kg for bariatric patient and 8.3kg for patients who followed a very low calorie diet.

Professor Tan commented: “Although the weight loss was smaller, using the GOP infusion would be preferable as it has fewer side effects than bariatric surgery. This result shows that it is possible to obtain some of the benefits of a gastric bypass operation without undergoing the surgery itself. If further trials are successful, in future we could potentially give this type of treatment to many more patients.”

The team also found that GOP was capable of lowering blood glucose levels to near-normal levels, with little variation in the blood glucose. Patients who received bariatric surgery also had an overall improvement in blood glucose, but the levels were much more variable, leaving them vulnerable to low blood glucose levels.

The team aim to carry out a larger clinical trial to assess the impact of GOP on more patients over a longer period of time.

The research was funded by the UK Medical Research Council (MRC) and the NIHR Imperial Biomedical Research Centre.

This research is an example of the work carried out by Imperial College Academic Health Science Centre, a joint initiative between Imperial College London and three NHS hospital trusts. It aims to transform healthcare by turning scientific discoveries into medical advances to benefit local, national and global populations in as fast a timeframe as possible.

The post New hormone injection aids weight loss in obese patients appeared first on MyMedicPlus.